Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 241 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Control Form 6 Clear all
Completed Phase 2 Interventional Results available

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

NCT01484275
View directory record Official record
Conditions
High-risk Smoldering Multiple Myeloma
Interventions
Siltuximab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
8
States / cities
Chicago, Illinois • Rockville, Maryland • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children

NCT01893554
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV ΔNS2 Δ1313 I1314L Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Months to 59 Months
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 30, 2026, 11:32 AM EDT
Terminated Phase 1 Interventional

Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome

NCT00839501
View directory record Official record
Conditions
Andersen-Tawil Syndrome
Interventions
Potassium, Acetazolamide
Dietary Supplement · Drug
Lead sponsor
University of Rochester
Other
Eligibility
10 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 30, 2026, 11:32 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Using Nicotine to Reverse Age-related Auditory Processing Deficits

NCT04971954
View directory record Official record
Conditions
Auditory Perceptual Impairment, Aging
Interventions
Nicotine gum, Placebo gum
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Irvine, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

NCT02346240
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Etanercept, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 30, 2026, 11:32 AM EDT
Terminated Phase 3 Interventional Results available

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

NCT02263508
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene Laherparepvec, Pembrolizumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 95 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A New Paradigm for Vitamin D Sufficiency

NCT02969850
View directory record Official record
Conditions
New Biomarkers for Measuring Vitamin D Level
Interventions
Vitamin D Supplementation, Placebo, Calcium
Dietary Supplement · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 90 Years · Female only
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Phase 3 Interventional Results available

A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)

NCT01604343
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Sirukumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
48
States / cities
Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age

NCT03102034
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
D46/NS2/N/ΔM2-2-HindIII, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

NCT06128733
View directory record Official record
Conditions
Meningococcal Immunisation, Healthy Volunteers
Interventions
Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine, Placebo, MenABCYW conjugate vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years to 25 Years
Enrollment
1,215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
46
States / cities
Birmingham, Alabama • Guntersville, Alabama • Tempe, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3

NCT01336699
View directory record Official record
Conditions
Shigella Infection
Interventions
Placebo, WRSs2, WRSs3
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

NCT03066804
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
sacubitril/valsartan, Enalapril, Valsartan, Placebo to match sacubitril/valsartan, Placebo to match enalapril, Placebo to match valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
2,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Andalusia, Alabama • Mobile, Alabama • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

NCT01968083
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV cps2 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
5
States / cities
La Jolla, California • Long Beach, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE

NCT04643067
View directory record Official record
Conditions
SLE; Drug
Interventions
KPG-818 low dose in phase 1b, KPG-818 mid dose in phase 1b, KPG-818 high dose in phase 1b, KPG-818 ultra-high dose in phase 1b, KPG-818 low dose in phase 2a, KPG-818 mid dose in phase 2a, KPG-818 high dose in phase 2a, KPG-818 Placebo in phase 2a
Drug
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
Anniston, Alabama • Birmingham, Alabama • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers

NCT05642546
View directory record Official record
Conditions
Healthy
Interventions
NM8074, Placebo
Drug
Lead sponsor
NovelMed Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 30, 2026, 11:32 AM EDT
Recruiting Phase 1 Interventional

Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria

NCT06559618
View directory record Official record
Conditions
Bacteriuria, Spinal Cord Injuries, Asymptomatic Bacteriuria, Escherichia Coli
Interventions
Phage Therapy, Placebo
Drug · Other
Lead sponsor
Barbara Trautner
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine

NCT01255410
View directory record Official record
Conditions
Metapneumovirus
Interventions
10^6 PFU rHMPV-Pa vaccine, 10^5 PFU rHMPV-Pa vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

NCT01824290
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Tadalafil, Placebo, ERA as specific PAH treatment
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
7
States / cities
Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 30, 2026, 11:32 AM EDT
Active, not recruiting Phase 2 Interventional

This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC

NCT07723924
View directory record Official record
Conditions
Functional Constipation (FC)
Interventions
plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Saraland, Alabama + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 11:32 AM EDT
Terminated Phase 3 Interventional Results available

Post-operative Course of Dexamethasone to Reduce Tonsillectomy Morbidity

NCT04879823
View directory record Official record
Conditions
Adenotonsillectomy, Analgesia, Surgery
Interventions
Dexamethasone, Ibuprofen, Acetaminophen, Placebo
Drug
Lead sponsor
David Chi, MD
Other
Eligibility
3 Years to 17 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Sewickley, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

NCT01560923
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Indoximod, Sipuleucel-T, Placebo
Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Phase 3 Interventional Results available

A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)

NCT01606761
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Sirukumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
81
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Phase 2 Interventional Results available

Energy Metabolism in Thyroidectomized Patients

NCT04782856
View directory record Official record
Conditions
Thyroid Goiter, Hypothyroidism, Thyroid Cancer
Interventions
Levothyroxine, Liothyronine, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 89 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 30, 2026, 11:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age

NCT03227029
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV ΔNS2/Δ1313/I1314L, RSV 276, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 30, 2026, 11:32 AM EDT